VGYAAN Pharmaceuticals

What VGYAAN Pharmaceuticals does

VGYAAN Pharmaceuticals LLC is a U.S.-based specialty pharmaceutical company focused on developing and commercializing clinically critical therapies across multiple dosage forms and therapeutic categories, including generic drugs and 505(b)(2) products. Founded in 2015 and headquartered in Skillman, New Jersey, the company commercialized a basket of niche generic drugs — Clomipramine Hydrochloride Capsules (psychotropic, generic of ANAFRANIL®), Leuprolide Acetate Injection (oncology, generic of LUPRON®), Nadolol Tablets (cardiovascular, generic of CORGARD®), Ursodiol Capsules (digestive/biliary, generic of ACTIGALL®), and Carbamazepine Tablets (neurological, generic of TEGRETOL®) — and held a tentative FDA approval for Selexipag Tablets (pulmonary arterial hypertension, generic of UPTRAVI®). The firm operated with a lean 1–10 employee team and positioned itself around supply-chain integrity and the explicit mission of mitigating drug shortages.\n\nThe business model centered on developing and commercializing generic and 505(b)(2) drugs through standard U.S. pharmaceutical distribution channels (wholesalers and distributors) supplemented by a December 2021 joint venture with Premier Inc., a healthcare improvement company connecting approximately 4,400 U.S. hospitals and health systems, designed to improve supply-chain reliability for shortage-prone therapies. VGYAAN also joined the End Drug Shortages Alliance in March 2023, deepening its positioning as a shortage-mitigation partner. The company was acquired by RK Pharma Inc. on June 15, 2023, and now operates as a subsidiary of RK Pharma.

Name

VGYAAN Pharmaceuticals

Legal name

VGYAAN Pharmaceuticals LLC

Website

https://vgyaan.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

1–10 employees

Short description

VGYAAN Pharmaceuticals is a U.S. specialty pharmaceutical company that develops and commercializes clinically critical generic and 505(b)(2) drugs for American healthcare providers and patients, focusing on shortage-prone therapies.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIABAL

Generic Hospital & Institutional Products

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Specialty pharmaceuticals
• Generic drugs
• 505(b)(2) drugs
• Clinical therapies
• Drug development

Headquarters

HQ city

Skillman

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Developing and commercializing generic drugs across various therapeutic categories and dosage forms.
2. 505(b)(2) Drugs: Developing and commercializing 505(b)(2) drugs which are modified versions of existing approved drugs, allowing for differentiated labeling and potential market advantages.

Distribution channels1 record

Core offering

VGYAAN Pharmaceuticals is a privately held specialty pharmaceutical company that develops and commercializes clinically critical therapies across a variety of dosage forms and therapeutic categories. Its portfolio includes generic drugs and 505(b)(2) drugs distributed through the US pharmaceutical supply chain. Products span therapeutic areas including psychotropic, anti-cancer, hypertension, and digestive/biliary disorder treatments.

Product overview

VGYAAN Pharmaceuticals is a US-based specialty pharmaceutical company focused on developing and commercializing clinically critical therapies across a variety of dosage forms and therapeutic categories. The company's product portfolio includes generic drugs and 505(b)(2) drugs. Commercialized products include: Clomipramine Hydrochloride Capsules (psychotropic agent, generic of ANAFRANIL®), Leuprolide Acetate Injection (anti-cancer, generic of LUPRON®), Nadolol Tablets (hypertension treatment, generic of CORGARD®), and Ursodiol Capsules (digestive/biliary disorder treatment, generic of ACTIGALL®). The company also has additional products in development or awaiting FDA approval.

Differentiator

Problem solved

Functional benefit

Products and services

• Clomipramine Hydrochloride Capsules, USP Generic psychotropic agent available in 25mg, 50mg, and 75mg strengths, serving as generic equivalent to ANAFRANIL®, for patients and healthcare providers treating depression and obsessive-compulsive disorder.
• Leuprolide Acetate Injection Multi-dose vial anti-cancer medication at 14mg/2.8mL (1mg/0.2mL), generic equivalent to LUPRON®, for oncology and hormone therapy applications.
• Nadolol Tablets, USP Generic hypertension medication available in 20mg, 40mg, and 80mg strengths, serving as generic equivalent to CORGARD®, for cardiovascular treatment.
• Ursodiol Capsules USP Generic medication at 300mg for digestive and biliary disorders, serving as generic equivalent to ACTIGALL®, for hepatobiliary therapy.
• Carbamazepine Tablets USP, 200 mg Generic anticonvulsant tablet at 200mg strength, serving as generic equivalent to TEGRETOL®, for epilepsy and bipolar disorder treatment.
• Selexipag Tablets Generic version of UPTRAVI® for pulmonary arterial hypertension (PAH) treatment, receiving tentative FDA approval.

Quantifiable outcome

• Multiple FDA approvals for generic drugs including Clomipramine, Leuprolide, Nadolol, Ursodiol, Carbamazepine
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• End Drug Shortages AlliancecoreStrategic or Co-development Partner · 8 March 2023VGYAAN Pharmaceuticals joined the End Drug Shortages Alliance, a coalition focused on improving the supply chain and addressing drug shortages in the United States. The alliance brings together pharmaceutical companies, healthcare providers, and other stakeholders to ensure reliable access to essential medications.
• Premier Inc.coreStrategic or Co-development Partner · 7 December 2021Premier Inc. formed a joint venture with VGYAAN Pharmaceuticals that launched its first product. Premier is a healthcare improvement company connecting approximately 4,400 U.S. hospitals and health systems. The joint venture aims to address drug shortages and improve supply chain reliability.
• R&D OrganizationsminorOthersThe genesis of VGYAAN Pharmaceuticals stems from collaboration with key stakeholders across the pharmaceutical value chain, including R&D organizations for product development.
• API ManufacturersminorOthersPartnership with API (Active Pharmaceutical Ingredient) manufacturers to ensure supply chain integrity and quality for pharmaceutical production.
• Contract ManufacturersminorOthersCollaboration with contract manufacturers for product development and commercialization across various dosage forms.
• Pharmaceutical CompaniesminorOthersPartnership with pharmaceutical companies for product development and commercialization of clinically critical therapies.

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lannett Company: Lannett is a US-based generic pharmaceutical developer and manufacturer with a portfolio spanning multiple therapeutic categories and dosage forms — closely mirroring VGYAAN's generic-focused model and US distribution approach.
• ANI Pharmaceuticals: ANI Pharmaceuticals is a US specialty pharmaceutical company developing, manufacturing, and marketing generic and branded prescription pharmaceuticals — directly comparable to VGYAAN in business model, therapeutic breadth, and 505(b)(2) strategy.
• Amneal Pharmaceuticals: Amneal Pharmaceuticals is a US-based generic and specialty pharmaceutical company offering a broad portfolio of generics, injectables, and specialty products — a close comparable in therapeutic breadth and US-market focus.
• Upsher-Smith Laboratories: Upsher-Smith develops, manufactures, and markets generic and branded specialty pharmaceuticals in the US, with an analogous focus on smaller-portfolio, niche generic and specialty products.
• Alvogen: Alvogen is a privately held US-headquartered generic pharmaceutical company developing and commercializing generics across multiple therapeutic categories — comparable to VGYAAN's specialty/generic orientation and asset-light development model.
• Akorn Pharmaceuticals: Akorn is a US specialty pharmaceutical company focused on generics, branded specialty, and animal health — comparable in scale and US market focus to VGYAAN's specialty generic model.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Mallinckrodt is a US-based specialty pharmaceutical company with generics and specialty brands across multiple therapeutic categories — a larger incumbent in adjacent specialty/generic market segments.
• Sandoz (Novartis): Sandoz is the global generics and biosimilars division of Novartis, competing in many of the same therapeutic categories as VGYAAN — represents a broad incumbent in the generic pharmaceuticals space.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with broad therapeutic coverage including many molecules in VGYAAN's portfolio — operates as a broad incumbent rather than a direct niche competitor.
• Endo International: Endo International is a large US specialty and generic pharmaceutical company with a portfolio that spans generics, branded specialty, and sterile injectables — operating as a broader incumbent in the same addressable space as VGYAAN.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vgyaanpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VGYAAN Pharmaceuticals